Total Payments
$5,813
2024 Payments
$1,208
Companies
33
Transactions
361
Medicare Patients
4,973
Medicare Billing
$656,446
Payment Breakdown by Category
Food & Beverage$5,813 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,813 | 361 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,132 | 139 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $873.24 | 71 | $0 (2024) |
| Janssen Biotech, Inc. | $483.54 | 26 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $424.50 | 24 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $197.51 | 12 | $0 (2018) |
| Ardelyx, Inc. | $175.56 | 13 | $0 (2023) |
| Fresenius Kabi USA, LLC | $169.40 | 5 | $0 (2024) |
| GENZYME CORPORATION | $151.89 | 9 | $0 (2023) |
| Boston Scientific Corporation | $128.42 | 3 | $0 (2024) |
| Allergan, Inc. | $125.21 | 7 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,208 | 61 | ABBVIE INC. ($558.05) |
| 2023 | $1,025 | 51 | AbbVie Inc. ($437.49) |
| 2022 | $1,239 | 103 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($414.59) |
| 2021 | $535.29 | 33 | AbbVie Inc. ($339.94) |
| 2020 | $267.34 | 14 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($71.06) |
| 2019 | $226.98 | 16 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($74.98) |
| 2018 | $683.55 | 44 | Takeda Pharmaceuticals U.S.A., Inc. ($162.83) |
| 2017 | $627.71 | 39 | AbbVie, Inc. ($215.01) |
All Payment Transactions
361 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Immunology | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: Gastroenterology | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: LIVER DISEASE | ||||||
| 10/29/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.60 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: IMMUNOLOGY | ||||||
| 09/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/23/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Immunology | ||||||
| 09/12/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: LIVER DISEASE | ||||||
| 09/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: IMMUNOLOGY | ||||||
| 08/26/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Immunology | ||||||
| 08/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,120 | 1,284 | $837,329 | $152,477 |
| 2022 | 20 | 1,269 | 1,507 | $963,358 | $171,858 |
| 2021 | 19 | 1,416 | 1,765 | $939,760 | $190,938 |
| 2020 | 19 | 1,168 | 1,407 | $785,134 | $141,172 |
Total Patients
4,973
Total Services
5,963
Medicare Billing
$656,446
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 155 | 158 | $221,200 | $35,655 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 213 | 288 | $90,820 | $32,021 | 35.3% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2023 | 149 | 151 | $181,200 | $12,999 | 7.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 183 | 188 | $126,900 | $12,109 | 9.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 56 | 125 | $20,000 | $8,769 | 43.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 42 | 42 | $33,390 | $8,519 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $22,620 | $8,246 | 36.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 28 | 28 | $22,364 | $5,684 | 25.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 44 | 45 | $13,725 | $5,076 | 37.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 28 | $12,460 | $4,151 | 33.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 25 | 25 | $20,000 | $3,888 | 19.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 32 | 32 | $28,000 | $3,802 | 13.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $10,300 | $3,648 | 35.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 20 | $8,500 | $2,913 | 34.3% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 30 | 30 | $19,500 | $2,494 | 12.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 24 | 29 | $2,610 | $1,260 | 48.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 17 | $3,740 | $1,243 | 33.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 150 | 153 | $214,200 | $33,237 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 224 | 294 | $90,995 | $29,831 | 32.8% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2022 | 189 | 193 | $244,550 | $20,913 | 8.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 201 | 202 | $136,070 | $13,706 | 10.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 56 | 166 | $26,672 | $10,429 | 39.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 49 | $21,805 | $8,562 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $23,790 | $8,438 | 35.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 36 | 36 | $28,684 | $7,394 | 25.8% |
About Dr. Phillip Wolfe, M.D
Dr. Phillip Wolfe, M.D is a Gastroenterology healthcare provider based in Pleasanton, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710075411.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Phillip Wolfe, M.D has received a total of $5,813 in payments from pharmaceutical and medical device companies, with $1,208 received in 2024. These payments were reported across 361 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($5,813).
As a Medicare-enrolled provider, Wolfe has provided services to 4,973 Medicare beneficiaries, totaling 5,963 services with total Medicare billing of $656,446. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Pleasanton, CA
- Active Since 10/10/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1710075411
Products in Payments
- XIFAXAN (Drug) $607.85
- RINVOQ (Biological) $458.61
- LINZESS (Drug) $426.68
- STELARA (Biological) $326.56
- VIBERZI (Drug) $235.83
- CREON (Drug) $228.87
- TRULANCE (Drug) $221.25
- HUMIRA (Biological) $208.84
- MAVYRET (Drug) $199.73
- Trulance (Drug) $197.51
- DUPIXENT (Biological) $196.42
- Humira (Biological) $194.79
- IBSRELA (Drug) $175.56
- IDACIO (Biological) $169.40
- ENTYVIO (Biological) $144.90
- Entyvio (Biological) $136.03
- SKYRIZI (Biological) $121.12
- Creon (Drug) $105.71
- Amitiza (Drug) $95.81
- TREMFYA (Drug) $95.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.